Channel - PTHS Net earnings per share growth forecast for next year

Corporate company logo of Channel Therapeutics (PTHS)

The development of neuropreparations by Channel Therapeutics (PTHS) is independent of market cycles, while the environmental agenda necessitates a reduction in chemical emissions. Analysts' 12-month EPS growth targets smooth out reporting volatility, and the 74.20 mark captures this metric. Business flexibility relies on the commercialization of innovative molecules and the expansion of the strategic partner network within the pharmaceutical sector.

Channel (PTHS): Net earnings per share growth forecast for next year from 07/03/2025 to 11/12/2026

Summary analytical data breakdowns for channeltherapeutics.com (PTHS)

- price and consensus price forecast:
Price Chart Channel|PTHS - Fair Value Consensus
- issuer market value details:
Market Value Channel Therapeutics|PTHS - Total Enterprise Value
- company book value details:
Net Assets per Single Share Channel Therapeutics|PTHS - Company Book Value|Market Value to Book Value Ratio channeltherapeutics.com|PTHS - Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Channel Therapeutics|PTHS - Long-Term Indebtedness to Equity|Short-Term Debt to Equity Ratio Channel Therapeutics Corp|PTHS - Company Cumulative Debt|Debts to Book Capitalization Channel Therapeutics|PTHS - Company Long-Term Liabilities|Company Short-Term Debts Channel Therapeutics|Quick Ratio channeltherapeutics.com
- net income and valuation ratios data:
PTHS - Net Profit|Expected Profit Channel Therapeutics|PTHS - Price to Earnings Multiple|Future Price to Earnings Channel Therapeutics|PTHS - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Channel Therapeutics|PTHS - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Channel Therapeutics|PTHS - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months channeltherapeutics.com|PTHS - Earnings per share increase in current year|Expected earnings per share growth for next year Channel Therapeutics
Fundamental company analysis:Channel, PTHS
Finished products of Channel Therapeutics Inc.

The stability of raw material supplies for Channel Therapeutics (PTHS) neurological drugs directly impacts operational efficiency and bottom-line net income. This EPS growth trajectory for the coming year aggregates analyst earnings per share forecasts, reflecting market expectations regarding business growth rates. Sharp fluctuations in this indicator signal a revision of the asset's fundamental value and risks of capital freeze.

Analysis of competing companies

Net earnings per share growth forecast for next year Jazz Pharma|CYTK: Expected earnings per share trend next year|Net earnings per share growth forecast for next year PTC Therapeutics, Inc. (PTCT)|SRRK - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year Centessa CNTA|Dyne Therapeutics Inc - Net earnings per share growth forecast for next year|EWTX - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Rapport Corp|ALMS: Earnings growth forecast for next year|Net earnings per one share growth forecast for next year zevra.com ZVRA|Expected earnings per share growth for next year CTNM|Expected net earnings per share growth next year Larimar Therapeutics Inc LRMR|Earnings growth forecast for next year CAPR|Expected earnings per share growth for next year Entrada Therapeutics, Inc TRDA|Earnings growth forecast for next year MNOV (MediciNova)|Expected earnings per share trend next year SER|BioXcel Therapeutics, Inc. - Earnings growth forecast for next year|PMN - Earnings growth forecast for next year|apimedsus.com (APUS) - Net earnings per share growth forecast for next year|Projected earnings per share growth rate for next year AEON|Net earnings per share growth forecast for next year NLS Pharmaceutics Ltd.|Projected earnings per share growth rate for next year BNOX (Bionomics Ltd)|Earnings growth forecast for next year HUGE|RETA - Expected net earnings per share growth next year